TITLE

ANCA-positive glomerulonephritis and IgA nephropathy in a patient on propylthiouracil

AUTHOR(S)

Winters, M. J.; Morrison Hurley, R.; Lirenman, David S.

PUB. DATE

April 2002

SOURCE

Pediatric Nephrology;Apr2002, Vol. 17 Issue 4, p257

SOURCE TYPE

Academic Journal

DOC. TYPE

Article

ABSTRACT

A 14-year-old girl developed acute renal failure after 3 years therapy with propylthiouracil (PTU) for Grave�s disease. Serologic evaluation showed antineutrophil cytoplasmic antibodies (ANCA) directed against proteinase 3 and myeloperoxidase. Renal biopsy showed a crescentic glomerulonephritis (GN) as well as evidence of IgA nephropathy (IgAN). PTU was discontinued and the patient was treated with prednisone and cyclophosphamide. ANCA became negative and renal function improved, but did not normalize. A second biopsy showed evidence of IgA nephropathy only. Propylthiouracil use has been associated with ANCA positive pauci-immune glomerulonephritis, but not with IgA nephropathy. An overlap syndrome between IgAN and ANCA-positive GN, however, has been described. This patient may have had a preexisting IgAN, with acute pauci-immune GN secondary to PTU, or this may be the first description of an overlap syndrome of IgAN and ANCA vasculitis all caused by PTU therapy.

ACCESSION #

6446977

Tags: GLOMERULONEPHRITIS;  IGA glomerulonephritis;  HYPERTHYROIDISM

 

Related Articles

• The genetic variants at the HLA-DRB1 gene are associated with primary IgA nephropathy in Han Chinese.  // BMC Medical Genetics;2012, Vol. 13 Issue 1, p33 

  The article presents a research that investigates the correlation between Immunoglobulin A nephropathy (IgAN) and HLA-DRB1 genes in the primary IgA nephropathy in Han Chinese in Beijing, China. Researchers studied 192 patients with IgAN using PCR-SSP technique. They found that HLA-DRB1*04 is...

• Does growth hormone therapy induce IgA nephropathy? Kano, Kenichi; Nishikura, Kiyoshi; Arisaka, Osamu // Pediatric Nephrology;Dec2005, Vol. 20 Issue 12, p1821 

  Presents a letter to the editor regarding the capacity of growth hormone therapy to induce immunoglobulin A nephropathy.

• Renal survival in pediatric patients with IgA nephropathy. Hastings, M.; Delos Santos, Noel; Wyatt, Robert // Pediatric Nephrology;Feb2007, Vol. 22 Issue 2, p317 

  A letter to the editor is presented in response to the article about IgA nephropathy in children.

• T235 Variant of AGT Gene Predicts IgA Nephropathy.  // Kidney;Mar/Apr98, Vol. 7 Issue 2, p59 

  Discusses the abstract of the article 'Association of angiotensin gene T235 variant with progression of immunoglobulin A nephropathy in Caucasian patients,' by Pei Y., J. Scholey, K. Thai et al, published in the 1997 issue of the 'Journal of Clinical Investigation.'

• Megsin: The First Biologic Marker for Injured Mesangial Cells.  // Kidney;Mar/Apr99, Vol. 8 Issue 2, p56 

  Reports on the cloning and characterization of a new human mesangium-predominant gene, megsin, a new member of the serpin superfamily that is upregulated in IgA nephropathy (IgAN), a form of mesangial proliferative glomerulephritis. Expression of megsin in normal human mesangial cells; Outcome...

• Diet Affects the Risk for IgA Nephropathy.  // Kidney;Nov/Dec99, Vol. 8 Issue 6, p239 

  Focuses on the medical history and lifestyle risk factors for immunoglobulin A (IgA) nephropathy in Japan. Conditions found to be protective against IgA nephropathy.

• Continue Immunosuppression in Presence of MPO-ab.  // Kidney;May/Jun98, Vol. 7 Issue 3, p108 

  Discusses the abstract of the research paper entitled 'Rapidly progressive IgA nephropathy with antimyeloperoxidase antibodies benefits from immunosuppression,' by E. Allmaras, R. Nowack et al and published in a 1997 issue of the journal 'Clinical Nephrology.'

• An adolescent with IgA nephropathy and Crohn disease: pathogenetic implications. Takemura, Tsukasa; Okada, Mitsuru; Yagi, Kazuro; Kuwajima, Hiroaki; Yanagida, Hidehiko // Pediatric Nephrology;Oct2002, Vol. 17 Issue 10, p863 

  We describe a patient with IgA nephropathy associated with Crohn disease. IgA nephropathy first appeared at the age of 10 years. Combined therapy with prednisolone, cyclophosphamide, warfarin, and angiotensin-converting enzyme inhibitor resulted in clinical improvement over the following year,...

• IgA nephropathy. Williams, D. Gwyn // BMJ: British Medical Journal (International Edition);1/8/94, Vol. 308 Issue 6921, p74 

  Discusses the clinical features of IgA nephropathy. Cause of the deposition of immunoglobulin A in the glomeruli; Production of IgA in the bone marrow; Aim of tonsillectomy in the treatment of the disease.

Read the Article